Prediabetes reversal hope: new drug combo tested in major trial

NCT ID NCT07558525

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a medication called chiglitazar sodium, combined with healthy lifestyle changes, can help people with prediabetes return to normal blood sugar levels. About 472 adults with prediabetes will take either the drug or a placebo for 52 weeks, along with lifestyle coaching. The main goal is to see how many achieve normal glucose metabolism by week 64, and to monitor for progression to type 2 diabetes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREDIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

  • Changsha Eighth Hospital

    Changsha, Hunan, China

  • Chengdu First People's Hospital

    Chengdu, Sichuan, 610499, China

  • Emergency General Hospital

    Beijing, China

  • Heji Hospital Affiliated to Changzhi Medical College

    Changzhi, Shanxi, China

  • Loudi Central Hospital

    Loudi, Hunan, China

  • People's Hospital of Hunan Province

    Changsha, Hunan, China

  • Quanzhou First Hospital, Fujian

    Quanzhou, Fujian, China

  • Shanghai Ninth People's Hospital

    Shanghai, China

  • Shenzhen Bao'an People's Hospital

    Shenzhen, China

  • Shenzhen Bao'an Traditional Chinese Medicine Hospital

    Shenzhen, China

  • Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

    Chengdu, Sichuan, 610072, China

  • Sir Run Run Hospital, Nanjing Medical University

    Nanjing, Jiangsu, China

  • The Central Hospital of Xiangtan

    Xiangtan, Hunan, China

  • The Central Hospital of Yongzhou

    Yongzhou, Hunan, China

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China

  • The First Affiliated Hospital of Henan University of Science & Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • The First Hospital of Harbin

    Harbin, Heilongjiang, 150010, China

  • The First People's Hospital of Changde City

    Changde, Hunan, China

  • The Second Affiliated Hospital Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China

  • The Second Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, 150086, China

  • The Second Xiangya Hospital, Central South University

    Changsha, Hunan, 410011, China

  • The Southwest Hospital of the Army Medical University

    Chongqing, 400038, China

  • The Third People's Hospital of Chengdu

    Chengdu, Sichuan, 610036, China

  • The Third Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Tongji Hospital of Tongji University

    Shanghai, China

  • Xuanwu Hospital Capital Medical University

    Beijing, China

  • Yueyang People's Hospital

    Yueyang, Hunan, China

  • Zhongnan Hospital of Wuhan University

    Wuhan, Hubei, 430071, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.